The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Mixing RU58841 with a solution for hair loss treatment, with suggestions to use propylene glycol and ethanol instead of k&b solution due to scalp irritation. Recommendations include using ketoconazole shampoo for itchiness and considering oral minoxidil if topical causes irritation.
The conversation discusses experiences with topical dutasteride for hair loss, comparing formulations from FUEClinic, MinoxidilMax, and Strut. Users share their results and side effects, with some preferring topical over oral treatments to minimize systemic absorption.
The conversation discusses hair loss treatments, specifically oral Minoxidil, also known as Loniten or Alotendin in Bulgaria. It also mentions considering IndiaMart for purchasing options.
Topical spironolactone is more effective than topical finasteride for treating hair loss in both men and women. Oral spironolactone can affect testosterone, but the topical form doesn't impact the endocrine system.
Use a stamp or roller for microneedling; stamps are preferred to avoid hair pulling. Clean tools with alcohol to prevent infection, and replace stamps every 4-6 uses.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The conversation discusses new research on hair growth by Dr. Maksim Plikus, with a call for clinical trials to begin. No specific treatments are mentioned.
The user is seeking a knowledgeable trichologist or dermatologist in Belgium for a thorough scalp examination due to diffuse thinning and a previous diagnosis of male pattern baldness. They are interested in procedures like a trichogram and scalp biopsy.
A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
The conversation discusses using liquid cetirizine as a topical treatment for hair loss. It mentions Minoxidil, finasteride, and RU58841 as other treatments.
The user is experiencing hair regrowth after using spironolactone, minoxidil 5%, and various supplements. They plan to purchase men's minoxidil for cost efficiency and use Nizoral shampoo and an oil blend for hair care.
The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.
The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.
The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.
A 20-year-old with diffused thinning is using oral minoxidil for androgenetic alopecia. They plan to switch to topical minoxidil, finasteride, and bimatoprost, and may consider surgery if their condition improves.
Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.
Minoxidil use may worsen seborrheic dermatitis, causing itching and dandruff. Users consider stopping minoxidil or switching to foam to improve scalp condition.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
A 30-year-old male is considering using dutasteride and fluridil for hair loss maintenance and is curious about the effectiveness of topical spironolactone, as he cannot take finasteride. He is also planning a hair transplant.
Hair cloning for hair loss is unlikely to be available or affordable in the next 10 years. Current treatments like Minoxidil, finasteride, and RU58841 are still the main options, with skepticism about new advancements.
Bryan Johnson uses topical dutasteride, minoxidil, and microneedling for hair loss. Users discuss treatment effectiveness and side effects, debating topical versus oral dutasteride efficacy.
A user with medium length hair and thinning at the top is using an adenosine-based hair growth serum and seeking advice on whether to use a boar bristle or nylon bristle brush to stimulate hair growth. They are concerned about their sensitive scalp.
The conversation discusses using topical spironolactone for hair loss, with the original poster already using oral and topical minoxidil, dutasteride, and latanoprost. Opinions differ on the effectiveness and safety of adding spironolactone, with some users suggesting alternative treatments like finasteride and vitamin supplements.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Topical and oral spironolactone show potential in improving hair growth when combined with topical Minoxidil.